Sanofi Pasteur MSD Limited

Mallards Reach, Bridge Avenue, Maidenhead, Berkshire, SL6 1QP
Telephone: +44 (0)1628 785 291
Fax: +44 (0)1628 671 722
Medical Information Direct Line: +44 (0)1628 587 693
Medical Information e-mail: medinfo@spmsd.com
Medical Information Fax: +44 (0)1628 635 072

Patient Information Leaflet last updated on the eMC: 26/07/2011
PIL Inactivated Influenza Vaccine (Split Virion) BP

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 26/07/2011 and displayed until Current
Reasons for adding or updating:
  • Change to Further Information section
Updated on 30/07/2010 and displayed until 26/07/2011
Reasons for adding or updating:
  • Change to Further Information section
Updated on 29/07/2010 and displayed until 30/07/2010
Reasons for adding or updating:
  • Change to Further Information section
Updated on 11/08/2009 and displayed until 29/07/2010
Reasons for adding or updating:
  • Change due to harmonisation of PIL.
  • Change of active ingredient
Updated on 01/07/2009 and displayed until 11/08/2009
Reasons for adding or updating:
  • Change due to harmonisation of PIL.
Updated on 29/08/2008 and displayed until 01/07/2009
Reasons for adding or updating:
  • Change to date of revision
  • PIL Retired pending re-submission
  • Change of active ingredient
Updated on 21/05/2008 and displayed until 29/08/2008
Reasons for adding or updating:
  • Change to date of revision
Updated on 17/08/2007 and displayed until 21/05/2008
Reasons for adding or updating:
  • Change of active ingredient
Updated on 06/11/2006 and displayed until 17/08/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 28/09/2006 and displayed until 06/11/2006
Reasons for adding or updating:
  • Change of active ingredient
  • Change to date of revision
Updated on 20/04/2006 and displayed until 28/09/2006
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Active Ingredients/Generics

 
   influenza vaccine